Methotrexate, a folic-acid antagonist and well-known anticancer drug, was first used to treat rheumatoid arthritis in the early 1950s [2.2] Because of growing interest in the use of immunosuppressive drugs in the treatment of rheumatoid arthritis, methotrexate received increasing attention in the late 1970s and early 1980s as a third-line agent [2.1, 2.3] for use in patients with disease refractory to first-line (nonsteroidal anti-inflammatory agents) and second-line agents (antimalarials, gold salts, or D-penicillamine).
Four placebo-controlled clinical trials [2.2, 3.11] have been published documenting the short-term clinical benefit of methotrexate. However, the benefits of long-term treatment are still unclear [3.22], and
Methotrexate in Rheumatoid Arthritis. Ann Intern Med. ;107:418–419. doi: 10.7326/0003-4819-107-2-418
Download citation file:
Published: Ann Intern Med. 1987;107(3):418-419.
Rheumatoid Arthritis, Rheumatology.
Results provided by:
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use